Encorafenib + Binimetinib + cemiplimab+fianlimab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma BRAF V600E/K Mutated

Conditions

Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

Trial Timeline

May 29, 2025 → Jan 1, 2028

NCT ID

NCT06887088

About Encorafenib + Binimetinib + cemiplimab+fianlimab

Encorafenib + Binimetinib + cemiplimab+fianlimab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Melanoma BRAF V600E/K Mutated. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06887088. Target conditions include Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma BRAF V600E/K Mutated were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06887088	Phase 2	Recruiting	May 29, 2025	Jan 1, 2028	Melanoma BRAF V600E/K Mutated

Competing Products

20 competing products in Melanoma BRAF V600E/K Mutated

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
AVT32-DRL_PB + Keytruda	Dr. Reddy's Laboratories	Phase 1	33
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35